Get the Flash Player to see this slideshow.
“Lazy eye” treatment improves amblyopic patients’ vision by enhancing brain processing without drugs, surgery or glasses.
Sunflower State makes big plays to attract industry
RevitalVision, LLC, announced today that its computer-based technology for eyesight improvement continues to be met with growing demand among vision care providers.
Spiritus Technologies, a start-up medical device company and LRTC client, has received a Kansas Technology Enterprise Corporation (KTEC) Proof of Concept grant.
St. Louis, MO - One of LRTC’s most recent additions to its client roster, AudioAnywhere, was given the opportunity to present at this year’s InvestMidwest event.
In March, LRTC announced that since 2003, its clients have raised over $180 million in investment capital.
Lawrence, KS – The Bioscience & Technology Business Center (BTBC) has just signed one of the region’s emerging pharmaceutical companies.
The University of Kansas’ status as a national leader in pharmacy research was reaffirmed today with the announcement that KU is second in the rankings of schools of pharmacy that receive National Institutes of Health research funding.
A new $7.25 million bioscience incubator on Kansas University’s West Campus will include all of the latest equipment, high-tech features and innovative partnerships demanded by a growing industry.
The Lawrence-Douglas County Biosciences Authority (LDCBA) will break ground on the $7.25 million Bioscience and Technology Business Center (BTBC) on the west campus of the University of Kansas October 5th at 11am.
The University of Kansas on Monday began construction of a $7.25 million complex that will provide space and support for fledgling biotech companies.
Proteon Founders Nicholas Franano, M.D. and William P. Whitaker, Esq. Named Ernst & Young Entrepreneur Of The Year® 2009 Award Winners in the Central Midwest Region.
Osteogenex has been selected for the "2009 Best of Kansas City Award" in the Commercial Medical Research category by the U.S. Commerce Association (USCA).
Proteon Therapeutics, Inc., has received an additional $12 million in venture capital.
Proteon Therapeutics Inc. reported two bits of good news Thursday: It has received an additional $38 million in equity financing, and it has granted Novartis AG the option to buy the company for $550 million.